

1           **Model-based estimates of deaths averted and cost per life saved by scaling-up mRNA**  
2           **COVID-19 vaccination in low and lower-middle income countries in the COVID-19**  
3           **Omicron variant era**

4  
5           Alexandra Savinkina, MSPH<sup>1,2</sup>, Alyssa Bilinski, PhD,<sup>3</sup> Meagan C. Fitzpatrick, PhD,<sup>4</sup> A. David  
6           Paltiel, PhD,<sup>2,5</sup> Zain Rizvi, JD,<sup>6</sup> Joshua A. Salomon, PhD,<sup>7</sup> Tommy Thornhill, MPH<sup>1,2</sup>, Gregg  
7           Gonsalves, PhD<sup>1,2</sup>  
8

- 9           1. Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven,  
10           CT  
11           2. Public Health Modeling Unit, Yale School of Public Health, New Haven, CT  
12           3. Departments of Health Services, Policy, and Practice & Biostatistics, Brown University School of  
13           Public Health, Providence, RI  
14           4. Center for Vaccine Development and Global Health, University of Maryland School of Medicine  
15           5. Department of Health Policy and Management, Yale School of Public Health, New Haven, CT  
16           6. Public Citizen, Washington, DC.  
17           7. Department of Health Policy, Stanford University, Palo Alto, CA USA

18  
19           **Abstract**

20  
21           **Background:** While almost 60% of the world has received at least one dose of COVID-19  
22           vaccine, the global distribution of vaccination has not been equitable. Only 4% of the population  
23           of low-income countries has received a full primary vaccine series, compared to over 70% of the  
24           population of high-income nations.  
25

26           **Methods:** We used economic and epidemiologic models, parameterized with public data on  
27           global vaccination and COVID-19 deaths, to estimate the potential benefits of scaling up  
28           vaccination programs in low and lower-middle income countries (LIC/LMIC) in 2022 in the  
29           context of global spread of the Omicron variant of SARS-CoV2. Outcomes were expressed as  
30           number of avertable deaths through vaccination, costs of scale-up, and cost per death averted.  
31           We conducted sensitivity analyses over a wide range of parameter estimates to account for  
32           uncertainty around key inputs.  
33

34           **Findings:** Global scale up of vaccination to provide two doses of mRNA vaccine to everyone in  
35           LIC/LMIC would cost \$35.5 billion and avert 1.3 million deaths from COVID-19, at a cost of  
36           \$26,900 per death averted. Scaling up vaccination to provide three doses of mRNA vaccine to  
37           everyone in LIC/LMIC would cost \$61.2 billion and avert 1.5 million deaths from COVID-19 at  
38           a cost of \$40,800 per death averted. Lower estimated infection fatality ratios, higher cost-per-  
39           dose, and lower vaccine effectiveness or uptake lead to higher cost-per-death averted estimates in  
40           the analysis.  
41

42           **Interpretation:** Scaling up COVID-19 global vaccination would avert millions of COVID-19  
43           deaths and represents a reasonable investment in the context of the value of a statistical life  
44           (VSL). Given the magnitude of expected mortality facing LIC/LMIC without vaccination, this  
45           effort should be an urgent priority.  
46  
47

## 48 Introduction

49  
50 As of January 7 2022, 59% of the global population had received at least one dose of a COVID-  
51 19 vaccine, 50% had received a full primary vaccine course, and 7% had received an additional  
52 booster. In low-income countries,<sup>1</sup> only 9% of people had received any dose of vaccine, and only  
53 4% had received two doses.<sup>2</sup> The barriers to global access to COVID-19 vaccines have been  
54 well-described. Many have emphasized the need to scale-up mRNA vaccine production to  
55 remedy these, including the transfer of technology for vaccine production to regional hubs to  
56 scale-up supply more quickly as recommend by the World Health Organization.<sup>3,4</sup> Beyond  
57 humanitarian implications, lingering inequities in access to COVID-19 vaccines will delay the  
58 worldwide recovery from the pandemic and continue to fuel the rise of new variants as the virus  
59 spreads in many parts of the globe.<sup>5</sup>

60  
61 Because the most dire complications of COVID-19 occur in older people and the age structure in  
62 many developing countries skews relatively young, it was initially assumed that the mortality  
63 burden in low (LIC) and lower-middle income countries (LMIC) from COVID-19 would be less  
64 severe.<sup>6</sup> However, deaths in LIC/LMIC have been growing as the pandemic has continued, likely  
65 due in part to underlying comorbidities.<sup>7</sup> LIC/LMIC now account for over 50% of the global  
66 mortality burden with some researchers suggesting they bear 80% of global COVID-19 mortality  
67 when accounting for underreporting of deaths in these regions.<sup>8</sup> Indeed, due to under-reporting,  
68 the recorded number of infections and deaths are likely gross under-estimates of the true burden  
69 of the pandemic in LIC/LMICs.<sup>9,10</sup> Model-based excess mortality estimates suggest that COVID-  
70 19-related mortality might be up to 35 times higher than reported figures in these settings.<sup>8,11</sup>

71  
72 The emergence of the Omicron variant has led to steep increases in infections and  
73 hospitalizations worldwide,<sup>12</sup> causing significant health losses and disruptions to daily life,  
74 commerce and travel, as well as severe stress on the healthcare sector dealing with a high volume  
75 of patients in many places across the globe. While Omicron appears to be less severe than other  
76 variants,<sup>13</sup> it is also more transmissible and more able to escape both existing immunity garnered  
77 by previous infections and that conferred through vaccination.<sup>14</sup>

78  
79 Previous literature has discussed the feasibility and costs of global vaccination for COVID-  
80 19,<sup>15,16</sup> placing the total cost somewhere between \$25 billion and \$50 billion.<sup>17,18</sup> However, the  
81 dangers of not vaccinating come at a potential worldwide cost of trillions of dollars.<sup>17,19</sup> WHO  
82 estimates a delivery cost per vaccine dose of about \$1.66, which together with vaccine  
83 production costs comes to a cost of about \$5 per dose in arm.<sup>15</sup> Even when incorporating higher  
84 vaccine prices as offered by manufacturers, the cost per dose delivered stays below \$10.

85  
86 This analysis aimed to estimate the number of deaths that could be averted via rapid scale up of  
87 vaccination in LIC/LMIC around the world, analyzing vaccination scenarios involving either two  
88 or three doses of mRNA vaccines. In addition, using estimates of the total cost of vaccine  
89 manufacturing and delivery, we evaluated the cost-per-death averted in LIC/LMIC. Our analysis  
90 provides lower and upper bounds on estimates of deaths averted under a broad range of  
91 assumptions and parameter values. Our study uses mRNA vaccines as the intervention, given  
92 that estimates for the costs of their rapid global scale-up are available,<sup>15</sup> the World Health

93 Organization is already setting up an mRNA production hub,<sup>16</sup> and they are among the most  
94 effective vaccines against COVID-19 to date, particularly against the Omicron variant.<sup>14,20</sup>  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138

## 139 **Methods**

140

### 141 **Analytic Approach**

142

143 We developed a model to assess potential deaths averted, total vaccination costs, and cost per  
144 death averted assuming vaccination scale up to 100% coverage in LIC/LMIC. We assumed the  
145 main COVID-19 variant to be Omicron, which leads to less severe disease than the prior Delta  
146 variant but has greater transmissibility and immune escape. The model assumed that all  
147 unvaccinated and previously uninfected individuals would be infected with COVID-19 within  
148 the year, and some percentage of those infected would die based on infection fatality ratios  
149 (IFRs) estimated for the Omicron variant for spike naïve, previously infected, and vaccinated  
150 individuals.

151

152 Our analysis of avertable deaths proceeded in three steps. First, we used mortality data (both  
153 estimates of excess mortality and reported COVID-19 deaths) over the last 22 months to estimate  
154 cumulative infections of COVID-19 across LIC/LMIC in all regions. Second, we used the  
155 number of previously infected people per country, the number of already vaccinated people per  
156 country, and the IFR to estimate a “number of avertable deaths” for future death from COVID-  
157 19, assuming those who are previously vaccinated and those who have previous immunity are  
158 protected at least in part. Third, we predicted the number of deaths that could be prevented based  
159 on estimated vaccine effectiveness.

160

161 We evaluated two potential dosage scenarios, one which estimates cost and effect of global  
162 vaccination with two doses of mRNA vaccine (“two-dose scenario”), and one with three doses of  
163 mRNA vaccine, the primary full course plus an additional booster (“three-dose scenario”). The  
164 two-dose scenario assumes that everyone who is unvaccinated at the start of the simulation will  
165 receive two doses, and those with one vaccine dose will receive an additional dose. The three-  
166 dose scenario calculation assumes those who are unvaccinated will receive three doses, those  
167 with two doses will receive one additional dose, and those with one dose will receive two  
168 additional doses. For cost calculations, we multiplied the number of doses needed for full  
169 population vaccination under these dosage scenarios by the cost per dose.

170

171 We estimated the number previously infected with COVID-19 in each region using estimates of  
172 regional COVID-19-related mortality and IFR:

173

174 [Eq. 1] 
$$I_i = (M_i / IFR_{p0}) / P_i$$

175

176

177  $I_i$  is the proportion of the population in region  $i$  with previous COVID-19 infection,  $M_i$  is the  
178 number of deaths attributed to COVID-19 since March 2020,  $IFR_{p0}$  is the infection fatality rate  
179 of COVID-19 pre-Omicron, and  $P_i$  is the population of region  $i$ .

180

181 As mortality due to COVID-19 is not well-measured in most LIC/LMIC, we estimate  $M_i$  in two  
182 ways. One method uses reported COVID-19 deaths as the COVID-19 mortality estimate, with  
183 the understanding that this would likely underestimate mortality due to COVID-19.

184 Alternatively, we use excess deaths estimates as the indicator of COVID-19 mortality.<sup>11</sup> The

185 modeled estimates of excess death have wide confidence intervals, and therefore we use both the  
186 median estimate and the 95% confidence limits in our analyses to reflect this uncertainty.

187  
188 We estimated the number of potentially avertible deaths ( $D_{i,d}$ ) from COVID-19 based on prior  
189 immunity and prior vaccination in each region with the two-dose and three-dose scenario:

190  
191 For two-dose scenario:

192  
193 [Eq. 2a] 
$$D_{i,2} = P_i * IFR_O * [I_i * (1 - V_i) * (1 - N) + (1 - I_i) * (1 - V_i)]$$

194  
195 For three-dose scenario:

196  
197 [Eq. 2b] 
$$D_{i,3} = P_i * IFR_{Omicron} * [I_i * (1 - V_i) * (1 - N) + (1 - I_i) * (1 - V_i) + I_i * V_i * (1 - E_2) * (1 - N) + (1 - I_i) * V_i * (1 - E_2)]$$

198  
199  
200  
201  $I_i$  is calculated in equation 1,  $IFR_O$  is the infection fatality rate of the Omicron variant of  
202 COVID-19,  $V_i$  is the proportion of the population in region  $i$  previously vaccinated with two  
203 doses of mRNA vaccine,  $N$  is the protection against mortality conferred by natural immunity,  
204 and  $E_2$  is the vaccine effectiveness against mortality for two doses of mRNA vaccine.

205  
206  
207 We then estimated the number of deaths averted ( $A_{i,d}$ ):

208  
209 For two-dose scenario:

210  
211 [Eq. 3a] 
$$A_{i,2} = D_{i,2} * E_2$$

212  
213 For three-dose scenario:

214  
215 [Eq. 3b] 
$$A_{i,3} = D_{i,3} * E_3$$

216  
217 Where  $E_3$  is the vaccine effectiveness against mortality from three doses of vaccine.

218  
219 We estimate the total number of vaccine doses necessary to fully vaccinate a region ( $X_{i,d}$ ):

220  
221 For two-dose scenario:

222  
223 [Eq. 4a] 
$$X_{i,2} = P_i (Y_i + 2 * (1 - Y_i - V_i))$$

224  
225  
226 For three-dose scenario:

227  
228 [Eq. 4b] 
$$X_{i,3} = P_i (V_i + 2 * Y_i + 3 * (1 - Y_i - V_i))$$

229  
230  $Y_i$  is the proportion of the population of region  $i$  vaccinated with only one dose of vaccine.

231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274

We estimated total cost of vaccination for each region ( $T_{i,d}$ ):

For two-dose scenario:

$$[Eq. 5a] \quad T_{i,2} = X_{i,2} * C$$

For three-dose scenario:

$$[Eq. 5b] \quad T_{i,3} = X_{i,3} * C$$

$X_i$  comes from equations 4a and 4b, and  $C$  was the cost per vaccine dose.

Finally, we estimated cost per death averted ( $Z_{i,d}$ ):

For two-dose scenario:

$$[Eq. 6a] \quad Z_{i,2} = \frac{T_{i,2}}{A_{i,2}}$$

For three-dose scenario:

$$[Eq. 6b] \quad Z_{i,3} = \frac{T_{i,3}}{A_{i,3}}$$

$T_{i,d}$  comes from equations 5a and 5b, and  $A_{i,d}$  comes from equations 3a and 3b.

## Parameter Values

Data on population by region and number of vaccinations came from Our World in Data and WHO (Table 1).<sup>2,12</sup> Data on reported COVID-19 mortality and excess mortality by region for 2020 and 2021 came from the Institute for Health Metrics and Evaluation and from *The Economist*.<sup>11,21</sup>

Countries were assigned to regions based on World Bank designations.<sup>1</sup> Only low-income (LIC) and lower-middle income countries (LMIC) were included in the main analysis. Population characteristics for each are shown in Table 1.

We extracted estimates of the infection fatality rate (IFR, for pre-Omicron and Omicron), natural immunity protection against mortality following past COVID-19 infection, vaccine effectiveness against mortality, and cost per dose of vaccine administered from the published literature (Table 2).

275  
276 For the base case analysis, we chose realistic parameter values with regards to the cost and  
277 benefits of scaling global COVID-19 vaccination. We set the COVID-19 Omicron variant IFR as  
278 one fifth of the pre-Omicron estimate (1 in 1,000 vs 5 in 1,000),<sup>13,22</sup> natural immunity protection  
279 against mortality as 80%,<sup>23</sup> and vaccine effectiveness against mortality as 80% for the two-dose  
280 scenario and 90% for the three-dose scenario (Table 1). Production and delivery of an mRNA  
281 vaccine dose was estimated to cost US\$7, the halfway point between relevant estimates of \$5 to  
282 \$10.<sup>15,16</sup>

## 283 284 **Sensitivity Analysis**

285  
286 Given the uncertainty surrounding several model parameters, we sought to assess the robustness  
287 of our conclusions under a wider range of assumptions about the values of our parameters alone  
288 and in combination. We therefore conducted a sensitivity analysis assessing the number of deaths  
289 averted and the cost-per-death averted while varying IFR, vaccine effectiveness, and vaccine  
290 cost. We ranged IFR from a “high” estimate of 5/1,000 consistent with pre-Omicron levels,<sup>22</sup> to a  
291 “low” estimate of 5/10,000, consistent with mortality reduction observed for Omicron in the  
292 US.<sup>24</sup> We ranged vaccine effectiveness against mortality for the two-dose scenario from 80% to  
293 95%, and for the three-dose scenario from 90% to 99%, given the uncertainty of vaccine  
294 effectiveness against Omicron as well as potential future variants.<sup>25</sup> Vaccine cost was ranged  
295 from \$5 to \$10 per dose (Table 1).

296  
297 As a scenario analysis, we examined the value of vaccines under imperfect uptake. For this  
298 analysis, avertible deaths were reduced from 100% to 75%, consistent with vaccine uptake  
299 observed in the United States. Cost for vaccine production was kept at 100%, with the  
300 assumption that enough vaccine is produced for full vaccination but uptake is reduced.

301  
302 We also assessed the potential benefit of vaccination in a scenario of high prior infection with  
303 COVID-19, since Omicron may spread through the world faster than vaccination can take place.  
304 This sensitivity analysis assumed that 100% of the population in LIC/LMIC would be previously  
305 infected by COVID-19 prior to vaccination, such that mortality risk is entirely among those with  
306 partial natural protection.

307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320

## 321 **Results**

322

### 323 **Base Case Analysis**

324

325 For the two-dose scenario with base case parameter estimates, using excess mortality to estimate  
326 prior infections and number at risk, scaling up vaccination to provide two doses of mRNA  
327 vaccine to everyone in LIC/LMIC would cost \$35.5 billion and avert 1.3 million deaths from  
328 COVID-19, at a cost of \$26,900 per death averted (Table 3). Scaling up vaccination to provide  
329 three doses of mRNA vaccine to everyone in LIC/LMIC would cost \$61.2 billion and avert 1.5  
330 million deaths from COVID-19 at a cost of \$40,800 per death averted (Table 3).

331

### 332 **Sensitivity Analysis**

333

334 We considered a wide range of values for IFR and vaccine effectiveness (Table 2). For the two-  
335 dose scenario, the cost-per-death averted ranged from \$4,500 when IFR was 5/1,000 and vaccine  
336 effectiveness against mortality was 95%, to \$53,800 when IFR was 5/10,000 and vaccine  
337 effectiveness against mortality was 80% (Figure 1). Deaths averted with the same parameter  
338 estimates ranged from 7.8 million to 0.7 million, respectively (Figure 2).

339

340 Considering an IFR of 1/1,000 and a vaccine effectiveness of 80% with the two-dose scenario,  
341 varying the cost-per-dose from \$5 to \$10 led to a range of cost-per-death estimates of \$19,200  
342 with a \$5 cost-per-dose to \$38,400 with a \$10 cost-per-dose (Figure 1).

343

344 Examining the implication of this parameter uncertainty for the three-dose scenario, the cost-per-  
345 death averted ranged from \$7,400 when IFR was 5/1,000 and vaccine effectiveness against  
346 mortality was 99% to \$81,500 when IFR was 5/10,000 and vaccine effectiveness against  
347 mortality was 90% (Figure 1). Deaths averted with the same parameter estimates ranged from 8.3  
348 million to 0.8 million, respectively (Figure 2).

349

350 Considering an IFR of 1/1,000 and a vaccine effectiveness of 80% with the three-dose scenario,  
351 varying the cost-per-dose from \$5 to \$10 led to a range of cost-per-death estimates of \$29,100  
352 with a \$5 cost-per-dose to \$58,200 with a \$10 cost-per-dose (Figure 1).

353

354

### 355 **Vaccine Hesitancy Analysis**

356

357 For the two-dose scenario with base case parameter estimates, using excess mortality to estimate  
358 prior infections and number at risk, reducing vaccine uptake to 75% but keeping cost at 100%  
359 would avert 1.0 million deaths at a cost of \$25,900 per death averted. When considering a wide  
360 range of values for IFR and vaccine effectiveness, cost-per-death averted ranged from \$7,200  
361 when IFR was 5/1,000 to \$71,700 when IFR was 5/10,000. Deaths averted with the same  
362 parameter estimates ranged from 5.0 million to 0.5 million, respectively.

363

364 For the three-dose scenario with base case parameter estimates, using excess mortality to  
365 estimate prior infections and number at risk, reducing vaccine uptake to 75% but keeping cost at  
366 100% would avert 1.2 million deaths at a cost of \$53,400 per death averted. When considering a

367 wide range of values for IFR and vaccine effectiveness, cost-per-death averted ranged from  
368 \$10,700 when IFR was 5/1,000 to \$107,700 when IFR was 5/10,000. Deaths averted with the  
369 same parameter estimates ranged from 4.7 million to 0.6 million, respectively.

370  
371

### 372 **All Previously Infected Scenario**

373

374 We finally considered a scenario in which Omicron infects 100% of LIC/LMIC population  
375 before vaccination is available, and all mortality risk occurs through re-infection. In this instance,  
376 the three-dose scenario with natural immunity protection against mortality of 80% and base case  
377 parameters leads to a cost-per-death averted at \$115,000, with 0.5 million deaths averted.

378

379 When varying IFR and vaccine effectiveness against mortality, with a cost-per-dose of \$7 cost-  
380 per-death averted ranged from \$20,900 with an IFR of 5/1,000 and vaccine effectiveness against  
381 mortality of 99% and \$230,000 with and IFR of 5/10,000 and vaccine effectiveness against  
382 mortality of 90%. Deaths averted with the same parameter estimates ranged from 2.9 million to  
383 0.3 million, respectively.

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

## 413 Discussion

414  
415 Our analysis suggests that scale-up of vaccination in LIC/LMIC is achievable at justifiable cost,  
416 with cost-per-death averted estimates between \$7,400 and \$81,500 for three doses of mRNA  
417 vaccine with a \$7 cost per dose. While the estimated cost-per-death averted in LIC/LMIC varies  
418 with estimated infection fatality ratio and vaccine effectiveness against a given COVID-19  
419 variant, all estimates of cost-per-death averted in our analysis are well below the commonly used  
420 estimates for the value of a statistical life (VSL), with accepted estimates ranging from €3.7  
421 million in Sweden to AUS\$7.3 million in Australia.<sup>26,27</sup> Even though cost to avert a death rises at  
422 lower COVID-19 IFR, lower vaccine effectiveness, and higher cost per dose, it is a fraction of  
423 the US 2022 VSL estimates of \$4.9 million - \$15.9 million.<sup>28</sup>

424  
425 Our current analysis focuses on the Omicron variant of COVID-19, a more transmissible but  
426 clinically less severe variant than those previously seen. When applying an infection fatality rate  
427 similar to that seen in previous variants of COVID-19, the number of deaths averted would rise  
428 to over 10 million and the cost-per-death averted would drop below \$10,000. If future variants of  
429 COVID-19 are more severe than Omicron, the imperative to vaccinate becomes more acute.

430  
431 Our model does not account for demographic differences among regions, including age structure  
432 and the prevalence of comorbid conditions which could affect COVID-19 mortality. Our analysis  
433 also did not include limitations on the capacity of health systems, which could affect mortality  
434 beyond what we capture with IFR. In addition, we do not attempt to model disease transmission  
435 dynamics, or include a temporal component in the model, so we assume anyone without  
436 immunity from vaccine or natural protection as of December 13, 2021 retains their risk of  
437 COVID-19 mortality through 2022. This is a major limitation given the speed with which the  
438 Omicron variant of COVID-19 has been spreading; however, our analysis considering  
439 vaccination scale-up after the whole population has been previously infected still estimates a  
440 cost-per-death averted of \$115,000. Finally, our main analysis uses reported deaths or excess  
441 mortality estimates to estimate rates of prior infection with COVID-19, which are inexact  
442 measures especially for the regions of most concern. Nevertheless, they are the best available  
443 estimates to date.

444 Experts have proposed several plans to rapidly expand global COVID-19 vaccine production and  
445 delivery.<sup>15,17,18</sup> However, the international community has not yet invested the resources required  
446 nor displayed the political commitment necessary to scale global vaccination. As a result, 86  
447 countries did not reach the World Health Organization's target of vaccinating 40 percent of their  
448 populations by the end of 2021.<sup>29</sup> This analysis shows that global vaccination can be undertaken  
449 for a fraction of the trillions of US\$ already spent on global COVID-19 response, and would  
450 avert deaths for a cost well below recognized VSL estimates. Whether the investment of US and  
451 other donor nations' resources for global COVID-19 vaccination are worth spending for this  
452 endeavor depends on how we value the lives in low and lower middle-income countries.

453  
454  
455  
456  
457

## 458 **References**

- 459
- 460 1. The World Bank. The World by Income and Region. 2022.
- 461 [https://datatopics.worldbank.org/world-development-indicators/the-world-by-income-and-](https://datatopics.worldbank.org/world-development-indicators/the-world-by-income-and-region.html)
- 462 [region.html](https://datatopics.worldbank.org/world-development-indicators/the-world-by-income-and-region.html) (accessed 1/17 2022).
- 463 2. Hannah Ritchie EM, Lucas Rodés-Guirao, Cameron Appel, Charlie Giattino, Esteban
- 464 Ortiz-Ospina, Joe Hasell, Bobbie Macdonald, Diana Beltekian, Max Roser. “Coronavirus
- 465 Pandemic (COVID-19)”. Published online at OurWorldInData.org. ; 2020.
- 466 3. Irwin A. What it will take to vaccinate the world against COVID-19. *Nature* 2021;
- 467 **592**(7853): 176-8.
- 468 4. Cohen J, Kupferschmidt K. Fairer shares. *Science* 2021; **372**(6545): 903-6.
- 469 5. Msomi N, Lessells R, Mlisana K, de Oliveira T. Africa: tackle HIV and COVID-19 together.
- 470 *Nature* 2021; **600**(7887): 33-6.
- 471 6. Mbow M, Lell B, Jochems SP, et al. COVID-19 in Africa: Dampening the storm? *Science*
- 472 2020; **369**(6504): 624-6.
- 473 7. Schellekens P. SD. COVID-19 Mortality in Rich and Poor Countries : A Tale of Two
- 474 Pandemics ? 2020. <https://ssrn.com/abstract=3614141> (accessed 12/11/21).
- 475 8. Indermit Gill PS. COVID-19 is a developing country pandemic. Future Development; The
- 476 Brookings Institution. 2021.
- 477 9. Whittaker C, Walker PGT, Alhaffar M, et al. Under-reporting of deaths limits our
- 478 understanding of true burden of covid-19. *Bmj* 2021; **375**: n2239.
- 479 10. Lau H, Khosrawipour V, Kocbach P, et al. Internationally lost COVID-19 cases. *J Microbiol*
- 480 *Immunol Infect* 2020; **53**(3): 454-8.
- 481 11. The Economist. The pandemic’s true death toll--Our daily estimate of excess deaths
- 482 around the world. 2021.
- 483 12. WHO COVID-19 Dashboard. . <https://covid19.who.int/> (accessed Jan 7 2021).
- 484 13. Abdullah F, Myers J, Basu D, et al. Decreased severity of disease during the first global
- 485 omicron variant covid-19 outbreak in a large hospital in tshwane, south africa. *Int J Infect Dis*
- 486 2021.
- 487 14. Rössler A, Riepler L, Bante D, Laer Dv, Kimpel J. SARS-CoV-2 B.1.1.529 variant (Omicron)
- 488 evades neutralization by sera from vaccinated and convalescent individuals. *medRxiv* 2021:
- 489 2021.12.08.21267491.
- 490 15. Zoltan K, Rizvi Z. How To Make Enough Vaccine for the World in One Year, 2021.
- 491 <https://www.citizen.org/article/how-to-make-enough-vaccine-for-the-world-in-one-year/>
- 492 (accessed 12/9/21).
- 493 16. World Health Organization (WHO). Establishment of a COVID-19 mRNA vaccine
- 494 technology transfer hub to scale up global manufacturing. 2021.
- 495 17. Ruchir Agarwal GG. A Proposal to End the COVID-19 Pandemic. International Monetary
- 496 Fund; 2021.
- 497 18. Public Citizen. \$25 Billion to Vaccinate the World. 2021.
- 498 <https://www.citizen.org/article/25-billion-to-vaccinate-the-world/>. (accessed 12/9/21)
- 499 19. Hafner M, Yerushalmi E, Fays C, Dufresne E, Van Stolk C. The global economic cost of
- 500 COVID-19 vaccine nationalism. Santa Monica, CA: RAND Corporation; 2020.

- 501 20. Garcia-Beltran WF, St Denis KJ, Hoelzemer A, et al. mRNA-based COVID-19 vaccine  
502 boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. *medRxiv* 2021:  
503 2021.12.14.21267755.
- 504 21. Institute for Health Metrics and Evaluation (IHME). COVID-19 Mortality,  
505 Infection,testing, Hospital resource Use, and Social Distancing Projections. Seattle, United  
506 States of America: Institute for Health Metrics and Evaluation (IHME), University of  
507 Washington,2020.
- 508 22. Levin A, Owusu-Boaitey N, Pugh S, et al. Assessing the Burden of COVID-19 in  
509 Developing Countries: Systematic Review, Meta-Analysis, and Public Policy Implications.  
510 *medRxiv* 2021: 2021.09.29.21264325.
- 511 23. Bozio CH, Grannis SJ, Naleway AL, et al. Laboratory-Confirmed COVID-19 Among Adults  
512 Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-  
513 CoV-2 Immunity - Nine States, January-September 2021. *MMWR Morb Mortal Wkly Rep* 2021;  
514 **70**(44): 1539-44.
- 515 24. Lewnard JA, Hong VX, Patel MM, Kahn R, Lipsitch M, Tartof SY. Clinical outcomes among  
516 patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California. *medRxiv*  
517 2022: 2022.01.11.22269045.
- 518 25. Colson P, Delerce J, Burel E, et al. Emergence in Southern France of a new SARS-CoV-2  
519 variant of probably Cameroonian origin harbouring both substitutions N501Y and E484K in the  
520 spike protein. *medRxiv* 2021: 2021.12.24.21268174.
- 521 26. Ananthapavan J, Moodie M, Milat AJ, Carter R. Systematic Review to Update 'Value of a  
522 Statistical Life' Estimates for Australia. *Int J Environ Res Public Health* 2021; **18**(11).
- 523 27. Hultkrantz L, Svensson M. The value of a statistical life in Sweden: a review of the  
524 empirical literature. *Health Policy* 2012; **108**(2-3): 302-10.
- 525 28. US Department of Health and Human Services. Guidelines for Regulatory Impact  
526 Analysis, 2016. In: Services UDoHaH, editor.; 2017.
- 527 29. International Monetary Fund (IMF). IMF Staff Proposal to End the COVID-19 Pandemic.  
528 2022. <https://www.imf.org/en/Topics/imf-and-covid19/imf-staff-pandemic-proposal>.(accessed  
529 1/9/22)
- 530 30. Sheikh A, Robertson C, Taylor B. BNT162b2 and ChAdOx1 nCoV-19 Vaccine Effectiveness  
531 against Death from the Delta Variant. *N Engl J Med* 2021; **385**(23): 2195-7.
- 532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542

543 **Table 1.** Population characteristics by region, low income and lower-middle income countries.  
 544  
 545

	<b>Total</b>	<b>Sub-Saharan Africa</b>	<b>Europe and Central Asia</b>	<b>Latin America and the Caribbean</b>	<b>South Asia</b>	<b>East Asia and the South Pacific</b>	<b>Middle East and North Africa</b>
<b>Characteristics</b>							
Population (millions)	3,669	1,092	98	46	1,876	303	253
% Vaccinated	37.4%	7.3%	32.6%	40.9%	54.3%	50.7%	27.3%
% Fully Vaccinated	24.3%	3.7%	22.9%	32.0%	34.2%	39.5%	20.9%
Number Reported COVID-19 Deaths (thousands)	945	54	110	35	566	103	77
Number Estimated Excess Deaths from COVID-19 (95% CI) (thousands)	9,309 (2,612-13,782)	1,393 (0-2,240)	272 (227-313)	154 (89-185)	6,495 (1,787-9,554)	438 (231-700)	556 (317-791)

546  
 547  
 548  
 549  
 550  
 551  
 552  
 553  
 554

555 **Table 2.** Model parameter estimates and ranges.  
 556

<b>Parameter</b>	<b>Base case parameters</b>	<b>Sensitivity Analysis</b>	<b>Source</b>
Infection fatality ratio (IFR) for pre-Omicron COVID-19	5/1,000		Levin et al. <sup>22</sup>
Infection fatality ratio (IFR) for Omicron variant of COVID-19	1/1,000	5/10,000 5/1,000	Levin et al. <sup>22</sup> Lewnard et al. <sup>24</sup> Abdullah et al. <sup>13</sup>
Natural immunity protection against COVID-19 mortality	80%		Bozio et al. <sup>23</sup>
Vaccine effectiveness against COVID-19 mortality, two dose	80%	80% 95%	Sheikh et al. <sup>30</sup>
Vaccine effectiveness against COVID-19 mortality, two dose + booster	90%	90% 99%	Sheikh et al. <sup>30</sup>
Cost per vaccine dose administered	\$7	\$5-\$10	Public Citizen <sup>15</sup> WHO <sup>16</sup>


557  
 558  
 559  
 560  
 561  
 562  
 563  
 564  
 565

566 **Table 3.** Model results for total cost of global vaccination of low and lower-middle income countries (in billions US\$), total deaths averted (in  
567 millions), and cost per death averted (US\$). The model assumes an IFR for pre-Omicron COVID: 5/1000, IFR for Omicron: 1/1,000, cost per dose  
568 \$7, natural immunity protection against mortality 80%, vaccine effectiveness against mortality with two doses: 80%, vaccine effectiveness against  
569 mortality with three doses: 90%.  
570

	<b>Two Dose Scenario</b>	<b>Three Dose Scenario</b>
<b>Total cost (US\$, billion)</b>	\$35.52	\$61.21
<b>Total vaccine doses needed (billion)</b>	5.07	8.74
<b>Total deaths averted (million)</b>		
Using reported COVID-19 deaths to calculate prior infection	2.14	2.40
Using excess mortality estimates to calculate prior infection (and 95% CI) <sub>1</sub>	1.32 (0.87-1.97)	1.50 (1.02-2.22)
<b>Cost per death averted (US\$)</b>		
Using reported COVID-19 deaths to calculate prior infection	\$16,700	\$25,500
Using excess mortality estimates to calculate prior infection (and 95% CI) <sub>1</sub>	\$26,900 (\$18,000-\$40,000)	\$40,800 (\$27,600-\$59,900)

571 1. 95% CI from excess mortality calculations from The Economist<sup>11</sup>  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592


593  
594



595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605

**Figure 1.** Sensitivity analysis looking at cost-per-death averted of vaccination in LIC/LMIC, ranging cost per vaccine dose, IFR and vaccine effectiveness against mortality in the two-dose scenario (first panel) and three-dose scenario (second panel). The y-axis shows cost-per-death averted in US\$, the x-axis shows cost per dose of vaccine in US\$. Solid lines show IFR of 5/10,000, dotted line shows IFR of 1/10,000, and dashed lines show IFR of 5/1,000. Dark red lines show baseline vaccine effectiveness (80% in two-dose scenario and 90% in three-dose scenario), and dark blue lines show high vaccine effectiveness (95% in two-dose scenario and 99% in three-dose scenario).

606  
607



608  
609  
610  
611  
612  
613  
614  
615  
616  
617

**Figure 2.** Sensitivity analysis looking at deaths averted of vaccination LIC/LMIC, ranging IFR and vaccine effectiveness against mortality in the two-dose scenario (first panel) and three-dose scenario (second panel). The y-axis shows deaths averted, in millions. The x-axis shows IFR. Dark red lines show baseline vaccine effectiveness (80% in two-dose scenario and 90% in three-dose scenario), and dark blue lines show high vaccine effectiveness (95% in two-dose scenario and 99% in three-dose scenario).



619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634